

**REGISTERED NUMBER: 07898798 (England and Wales)**

**Unaudited Financial Statements**  
**for the Year Ended 31 October 2017**  
**for**  
**Biosilico Limited**



**Biosilico Limited (Registered number: 07898798)**

**Contents of the Financial Statements  
for the year ended 31 October 2017**

	<b>Page</b>
<b>Company Information</b>	1
<b>Abridged Balance Sheet</b>	2
<b>Notes to the Financial Statements</b>	4



**Biosilico Limited**

**Company Information  
for the year ended 31 October 2017**

**DIRECTOR:** Dr A Kruse

**REGISTERED OFFICE:** Clitheroe Business Centre  
105 Whalley Road  
Clitheroe  
Lancashire  
BB7 1HW

**REGISTERED NUMBER:** 07898798 (England and Wales)

**ACCOUNTANTS:** Mayes Business Partnership Ltd  
Chartered Certified Accountants  
22-28 Willow Street  
Accrington  
Lancashire  
BB5 1LP



**Biosilico Limited (Registered number: 07898798)****Abridged Balance Sheet  
31 October 2017**

	Notes	31/10/17 £	£	31/10/16 £	£
<b>FIXED ASSETS</b>					
Intangible assets	4		5,500		7,500
Tangible assets	5		-		<u>242</u>
			<u>5,500</u>		<u>7,742</u>
<b>CURRENT ASSETS</b>					
Debtors		53,582		24,225	
Cash at bank		<u>1,806</u>		<u>1,897</u>	
		55,388		26,122	
<b>CREDITORS</b>					
Amounts falling due within one year		<u>51,539</u>		<u>27,659</u>	
<b>NET CURRENT ASSETS/(LIABILITIES)</b>			<u>3,849</u>		<u>(1,537)</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>			<u>9,349</u>		<u>6,205</u>
<b>CAPITAL AND RESERVES</b>					
Called up share capital			1		1
Retained earnings			<u>9,348</u>		<u>6,204</u>
<b>SHAREHOLDERS' FUNDS</b>			<u>9,349</u>		<u>6,205</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 October 2017.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 October 2017 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

- ensuring that the company keeps accounting records which comply with Sections 386 and 387
- (a) of the Companies Act 2006 and preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections
- (b) 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The notes form part of these financial statements

Page 2

continued...



**Biosilico Limited (Registered number: 07898798)**

**Abridged Balance Sheet - continued**  
**31 October 2017**

The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

All the members have consented to the preparation of an abridged Balance Sheet for the year ended 31 October 2017 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director on 31 July 2018 and were signed by:

Dr A Kruse - Director

The notes form part of these financial statements

**Biosilico Limited (Registered number: 07898798)**

**Notes to the Financial Statements  
for the year ended 31 October 2017**

**1. STATUTORY INFORMATION**

Biosilico Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

**2. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements have been prepared on a going concern basis. The company has net current liabilities in the previous financial year. The company is reliant on the continued support of the director, who is of the opinion that trading will improve. No adjustments have been made which may have been found necessary if any other basis of preparation had been used.

**Turnover**

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

**Intangible assets**

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents are being amortised evenly over their estimated useful life of ten years.

Research & development is being amortised evenly over its estimated useful life of five years.

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery etc - Straight line over 3 years

**Taxation**

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

**Deferred tax**

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to

the reversal of the  
timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. **EMPLOYEES AND DIRECTORS**

The average number of employees during the year was 2 .

continued...

**Biosilico Limited (Registered number: 07898798)****Notes to the Financial Statements - continued  
for the year ended 31 October 2017**

4.	<b>INTANGIBLE FIXED ASSETS</b>	Totals	
		£	
	<b>COST</b>		
	At 1 November 2016 and 31 October 2017	15,000	
	<b>AMORTISATION</b>		
	At 1 November 2016	7,500	
	Amortisation for year	<u>2,000</u>	
	At 31 October 2017	<u>9,500</u>	
	<b>NET BOOK VALUE</b>		
	At 31 October 2017	<u>5,500</u>	
	At 31 October 2016	<u>7,500</u>	
5.	<b>TANGIBLE FIXED ASSETS</b>	Totals	
		£	
	<b>COST</b>		
	At 1 November 2016 and 31 October 2017	1,923	
	<b>DEPRECIATION</b>		
	At 1 November 2016	1,681	
	Charge for year	<u>242</u>	
	At 31 October 2017	<u>1,923</u>	
	<b>NET BOOK VALUE</b>		
	At 31 October 2017	<u>-</u>	
	At 31 October 2016	<u>242</u>	
6.	<b>DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES</b>		
	The following advances and credits to a director subsisted during the years ended 31 October 2017 and 31 October 2016:		
		31/10/17	31/10/16
		£	£
	<b>Dr A Kruse</b>		
	Balance outstanding at start of year	(1)	(1)
	Amounts advanced	45,850	40,060
	Amounts repaid	(45,861)	(40,060)
	Amounts written off	-	-
	Amounts waived	-	-
	Balance outstanding at end of year	<u>(12)</u>	<u>(1)</u>



